20. January 2022

This article has been indexed from Lawfare

A photo of the E. Barrett Prettyman United States Court House, which houses the U.S. Court of Appeals for the District of Columbia Circuit. (NCinDC, https://flic.kr/p/5n8q1x; CC BY-ND 2.0, https://creativecommons.org/licenses/by-nd/2.0/)

AstraZeneca, Pfizer and Johnson & Johnson may be used to good press after developing and distributing millions of life-saving coronavirus vaccine doses. But 2022 is off to a less-auspicious start for these pharma giants. Back in 2017, a group of Americans who had been wounded by terrorist attacks carried out in Iraq by the militant group Jaysh al-Mahdi sued these companies and others for allegedly helping to finance the attacks by making corrupt payments to the Jaysh al-Mahdi-controlled Iraqi Ministry of Health. The U.S. District Court for the District of Columbia dismissed the case, Atchley v. AstraZeneca, in 2020, finding that the plaintiffs failed to adequately allege primary or seco

[…]

Content was cut in order to protect the source.Please visit the source for the rest of the article.

Read the original article: D.C. Circuit Opinion in Atchley v. AstraZeneca

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close